Successful management of maternal anti‐PP1P k alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin
Journal of Clinical Apheresis · 2024
DOI: 10.1002/jca.22120 ↗At a glance
Fallbericht in Journal of Clinical Apheresis, 2024. Written by Yannis Hadjiyannis and 10 co-authors. Institution: Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Major MEDLINE topics: Plasma Exchange, Immunoglobulins, Intravenous. Cited 2 times so far (Crossref); 22 references.
Abstract (original language)
Anti‐PP1P K alloimmunization is rare given ubiquitous P1PK expression. Prevention of recurrent miscarriages and hemolytic disease of the fetus and newborn (HDFN) in pregnant individuals with anti‐PP1P K antibodies has relied upon individual reports. Here, we demonstrate the successful management of maternal anti‐PP1P K alloimmunization in a 23‐year‐old, G2P0010, with therapeutic plasma exchange (TPE), intravenous immunoglobulin (IVIG), and monitoring of anti‐PP1P k titers. Twice‐weekly TPE (1.5 plasma volume [PV], 5% albumin replacement) with weekly titers and IVIG (1 g/kg) was initiated at 9 weeks of gestation (WG). The threshold titer was ≥16. Weekly middle cerebral artery‐peak systolic velocities (MCA‐PSV) for fetal anemia monitoring was initiated at 16 WG. PVs were adjusted throughout pregnancy based on treatment schedule, titers, and available albumin. Antigen‐negative, ABO‐compatible RBCs were obtained through the rare donor program and directed donation. An autologous blood autotransfusion system was reserved for delivery. Titers decreased from 128 to 8 by 10 WG. MCA‐PSV remained stable. At 24 WG, TPE decreased to once weekly. After titers increased to 32, twice‐weekly TPE resumed at 27 WG. Induction of labor was scheduled at 38 WG. Vaginal delivery of a 2950 g neonate (APGAR score: 9, 9) occurred without complication (Cord blood: 1+ IgG DAT; Anti‐PP1P k eluted). Newborn hemoglobin and bilirubin were unremarkable. Discharge occurred postpartum day 2. Anti‐PP1P k alloimmunization is rare but associated with recurrent miscarriages and HDFN. With multidisciplinary care, a successful pregnancy is possible with IVIG and TPE adjusted to PV and titers. We also propose a patient registry and comprehensive management plan.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Transfusion, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA.
- Clinical Aphersis, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA.
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
ORCID profiles: Yannis Hadjiyannis, Jennifer M Jones, Alesia Kaplan
Cite
APA
Hadjiyannis, Y., Jones, J. M., Chibisov, I., Kiss, J., Gabert, K., Sevcik, J., Bakdash, S., Binstock, A., Kilonsky, C., Parviainen, K., & Kaplan, A. (2024). Successful management of maternal anti‐PP1P k alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22120
Vancouver
Hadjiyannis Y, Jones JM, Chibisov I, Kiss J, Gabert K, Sevcik J, et al. Successful management of maternal anti‐PP1P k alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin. Journal of Clinical Apheresis. 2024. doi:10.1002/jca.22120
BibTeX
@article{Hadjiyannis2024,
author = {Hadjiyannis, Yannis and Jones, Jennifer M and Chibisov, Irina and Kiss, Joseph and Gabert, Kim and Sevcik, Joan and Bakdash, Suzanne and Binstock, Anna and Kilonsky, Carolyn and Parviainen, Kristiina and Kaplan, Alesia},
title = {Successful management of maternal anti‐PP1P k alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin},
journal = {Journal of Clinical Apheresis},
year = {2024},
doi = {10.1002/jca.22120}
}
EUVIMED